SOURCE: Inforsense, Ltd.

September 25, 2007 09:00 ET

University of North Carolina Leverages InforSense GenSense™ for Individualized Drug Therapy Research

Analytics Platform Enables High-Throughput Genotyping Analysis at University's Institute of Pharmacogenomics and Individualized Therapy

LONDON and CAMBRIDGE, MA--(Marketwire - September 25, 2007) - InforSense Ltd., the leading provider of embedded enterprise intelligence, today announced that the University of North Carolina at Chapel Hill's Institute of Pharmacogenomics and Individualized Therapy (IPIT) has implemented the company's GenSense workflow-based analytics platform as an integral part of its research to better match medicines with patients' unique, individual needs.

IPIT, the first research institute of its kind in the United States, works to create precise, effective treatment options for individual patients suffering from a wide range of conditions through pharmacogenomics -- the exploration of how our genes influence our response to drugs and the integration of pharmacology with modern advances in genome analysis.

"The Institute's interdisciplinary approach required a robust platform that could effectively analyze data from a wide range of sources," said Howard McLeod, Pharm.D., IPIT Director. "This seemed like an impossible task when we started the Institute a year ago, but with the help of InforSense GenSense, we are effectively combining these diverse data sources under one system. With its high-throughput genotyping analysis capabilities, InforSense GenSense has helped us make remarkable progress towards optimizing patient therapy."

The flexibility of the InforSense solution allows IPIT to draw from repositories of data residing in a number of disciplines. Using one platform, the Institute is able to leverage expression data, DNA and microarray analysis, electronic medical records, and various relational databases to drive its interdisciplinary research initiatives.

IPIT's work has resulted in changes in FDA guidelines for warfarin -- a blood thinner prescribed to more than 2 million people in the U.S, as well as therapies for colorectal cancer and childhood leukemia. When a drug goes through clinical trials, its effectiveness and side effects are determined based on a large population. However, there are dramatic differences among people in their reaction to a particular medicine. IPIT identifies specific genetic variants that predispose patients to risk of severe side effects or inadequate benefit from drugs for diseases.

"We are delighted that GenSense has enabled UNC's Institute to do such important work in individualized patient therapy," said Joseph F. Donahue, Senior Vice President at InforSense. "The comprehensive, out-of-the-box capabilities of GenSense make it easy for IPIT to change and update workflows to meet new requirements in this world of complex and constantly changing research data."

InforSense GenSense

InforSense GenSense enables the analysis of data from the latest generation of genotyping platforms. It has been specifically designed to assist researchers understand complex analyses, quickly find interesting SNPs and produce reports with easy to understand graphical summaries and interactive visualizations of large data sets. GenSense has achieved GeneChip-compatible™ status with the Affymetrix GeneChip® microarray platform and also supports data from Illumina and other standard genomics data sources such as Entrez Gene, HapMap and dbSNPs.

About InforSense

InforSense Ltd., the leader in embedded enterprise analytics, enables organizations to orchestrate and optimize their business-critical decision-making processes. Leading pharmaceutical and biotechnology, consumer goods, healthcare, financial services, manufacturing and communications companies are using the company's flagship product, InforSense, to enhance productivity by embedding analytics within their business processes. The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts.

For more information visit

InforSense and the InforSense logo are registered trademarks of InforSense Limited. GenSense is a trademark of InforSense Limited. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

Contact Information

  • Contact:
    Betsey Rogers
    Red Javelin Communications, Inc.
    Email Contact